文献速递骨肿瘤

骨肉瘤患者至高手术量医疗提供者的地理可及性与生存:美国全国模式

Geographic Access to High-Volume Care Providers and Survival in Patients with Bone Sarcomas: Nationwide Patterns in the United States.
PubMed 文献 · J Bone Joint Surg Am · 2022-06-21

该研究利用美国国家癌症数据库分析2004至2015年确诊的8432例骨肉瘤患者,发现旅行距离≥50英里者死亡风险低于≤10英里者(HR 0.69)。高手术量机构(≥20例/年)患者死亡风险低于低手术量机构(≤5例/年)(HR 0.72)。结论认为生存获益归因于患者前往高手术量机构就医,转诊路径的调整可能改善骨肉瘤患者生存。

要点

  • 旅行距离≥50英里(≥80.5公里)患者死亡风险低于≤10英里(≤16.1公里)患者,HR 0.69(95%CI 0.63-0.76)。
  • 高手术量机构(≥20例/年)患者死亡风险低于低手术量机构(≤5例/年),HR 0.72(95%CI 0.66-0.80)。
  • 旅行≥50英里至高手术量机构者死亡风险低于≤10英里至低手术量机构者,HR 0.65(95%CI 0.56-0.77)。

核心结论

  • 这项全国性研究显示,更大的旅行负担与成人更高的生存率相关,该发现归因于患者前往高手术量机构接受治疗。
  • 尽管旅行带来负担,调整转诊路径至专科中心可能改善骨肉瘤患者的生存。

研究设计与样本

  • 使用美国国家癌症数据库,纳入2004年至2015年确诊的8432例骨肉瘤患者。
  • 采用多因素Cox回归分析,控制社会人口学、临床和医院层面因素;按组织学诊断、肿瘤分期及儿童或成人状态进行亚组分层分析。
  • 证据等级为预后Level III。

主要发现

  • 旅行≥50英里(≥80.5公里)患者死亡风险低于旅行≤10英里(≤16.1公里)患者,HR 0.69(95%CI 0.63-0.76)。
  • 高手术量机构(≥20例/年)患者死亡风险低于低手术量机构(≤5例/年)患者,HR 0.72(95%CI 0.66-0.80)。
  • 在高手术量机构接受治疗的患者比例随旅行距离变化(p < 0.001):旅行≥50英里者最高为53%,旅行11至49英里(17.7至78.9公里)者为32%,旅行≤10英里者为18%。
  • 旅行≥50英里至高手术量机构的患者死亡风险低于旅行≤10英里至低手术量机构的患者,HR 0.65(95%CI 0.56-0.77)。
  • 亚组分析中,该关联在全部3种主要组织学亚型、I期、II期和IV期肿瘤患者及成人中均明显。

关键数值与推荐

  • 高手术量机构定义为≥20例/年,低手术量机构定义为≤5例/年。
  • 旅行距离分组:≥50英里(≥80.5公里)、11至49英里(17.7至78.9公里)、≤10英里(≤16.1公里)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical practice guidelines recommend centralized care for patients with bone sarcoma. However, the relationship between the distance that patients travel to obtain care, institutional treatment volume, and survival is unknown. METHODS: We used the National Cancer Database to examine associations between travel distance and survival among 8,432 patients with bone sarcoma diagnosed from 2004 to 2015. Associations were identified using multivariable Cox regression analyses that controlled for sociodemographic, clinical, and hospital-level factors; subgroup analyses stratified patients by histological diagnosis, tumor stage, and pediatric or adult status. RESULTS: Mortality risk was lower among patients who traveled ≥50 miles (≥80.5 km) than among patients who traveled ≤10 miles (≤16.1 km) (hazard ratio [HR], 0.69 [95% confidence interval (CI), 0.63 to 0.76]). Among hospital-level factors, facility volume independently affected survival: mortality risk was lower among patients at high-volume facilities (≥20 cases per year) than at low-volume facilities (≤5 cases per year), with an HR of 0.72 (95% CI, 0.66 to 0.80). The proportion of patients who received care at high-volume facilities varied by distance traveled (p < 0.001); it was highest among patients who traveled ≥50 miles (53%) and lower among those who traveled 11 to 49 miles (17.7 to 78.9 km) (32%) or ≤10 miles (18%). Patients who traveled ≥50 miles to a high-volume facility had a lower risk of mortality (HR, 0.65 [95% CI, 0.56 to 0.77]) than those who traveled ≤10 miles to a low-volume facility. In subgroup analyses, this association was evident among patients with all 3 major histological subtypes; those with stage-I, II, and IV tumors; and adults. CONCLUSIONS: This national study showed that greater travel burden was associated with higher survival rates in adults, a finding attributable to patients traveling to receive care at high-volume facilities. Despite the burdens associated with travel, modification of referral pathways to specialized centers may improve survival for patients with bone sarcoma. LEVEL OF EVIDENCE: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Fujiwara T, Ogura K, Alaqeel M, et al. Geographic Access to High-Volume Care Providers and Survival in Patients with Bone Sarcomas: Nationwide Patterns in the United States. J Bone Joint Surg Am. 2022. PMID: 35730765. doi:10.2106/JBJS.21.01140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。